Bristol Myers Squibb (BMY) offered to buy Mirati Therapeutics (MRTX) for up to $5.8 billion, but MRTX stock tumbled Monday on the lowball bid.
X
The deal values Mirati stock at $58 per share, representing a total $4.8 billion takeover price. But MRTX stock closed at 60.20 on Friday.
On Thursday, a Food and Drug Administration panel said the evidence backing Amgen‘s (AMGN) lung cancer treatment, Lumakras, a rival to a Mirati drug called Krazati, isn’t sufficient to support its accelerated approval. Now, it’s unclear whether the FDA will allow Amgen to keep Lumakras on the market. The same day, Bloomberg reported Sanofi (SNY) was looking to buy Mirati, and MRTX stock rocketed more than 45%.
Bristol’s offer includes a contingent value right worth $12 per share of MRTX stock. It will pay that if the FDA accepts an application for approval of Mirati’s drug, MRTX1719. The company is testing that drug in patients with a form of lung cancer. That would bring the total deal value up to $5.8 billion.
But Leerink Partners analyst Andrew Berens says Bristol’s offer is probably too low.
“We think another bidder could emerge given our assessment of Mirati’s strategic value and a number of near-term catalysts,” he said in a report. “Even with the consideration of the CVR, we think the $64 per share, $5.3 billion offer is significantly below what we see as the strategic value of the company.”
In premarket trading on today’s stock market, MRTX stock toppled 5.8%, trading near 56.70. Bristol stock also dipped 1.6% near 55.70.
More to follow.
Follow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.
YOU MAY ALSO LIKE:
The Point At Which IBD Stock Of The Day Eli Lilly Could Become Actionable Again
Teva Leans Into Sanofi’s ‘Pipeline-In-A-Product’ Expertise In $1.5 Billion Deal
Want More IBD Insights? Subscribe To Our Investing Podcast!
Find The Best Long-Term Investments With IBD Long-Term Leaders
Get Timely Buy & Sell Alerts With IBD Leaderboard
